Biocodex Selects PANTHERx as New Distributor for Diacomit
Diacomit was approved in 2018 for seizures associated with Dravet syndrome, a rare pediatric disorder.
Biocodex has selected PANTHERx Rare as the exclusive U.S. pharmacy distribution partner for Diacomit (stiripentol), which is available for the adjunctive treatment of seizures associated with Dravet syndrome in those 2 years of age and older taking clobazam. It is delivered as oral capsules or powder for oral suspension. The FDA had approved the therapy in August 2018.
Dravet syndrome, also known as severe myoclonic epilepsy infancy, is a rare epileptic disorder typically diagnosed in infancy occurring in 1 in 15,700 people in the United States. It is often characterized by temperature-sensitive seizures and febrile seizures that may be difficult to treat. The majority of infants with Dravet syndrome have a genetic mutation in the SCN1A gene. Dravet syndrome is a lifelong disorder that can be associated with severe complications and decreased quality of life. The mortality rate ranges from 3.7% to 17.5% with 15% and 61% of deaths attributed to sudden unexpected death in epilepsy.
"Our partnership will allow the Dravet syndrome community renewed hope for improved health outcomes,” Rob Snyder, president of PANTHERx, said in a press release. “We look forward to assisting the members of this rare patient population as they navigate their health journeys.”
